MRC1 and ocular melanoma: The immunomodulatory effect of OM-MSCs on activated microglia cells, specifically their transition from the proinflammatory M1 phenotype to the anti-inflammatory M2 phenotype, was investigated by assessing the expression levels of the anti-inflammatory marker CD206 and proinflammatory marker IL-1β in BV2 cells.